Drug intelligence / Profile preview

acipimox + insulin

Development stage: Unknown
Lead developer: Pfizer
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous, Intravenous

Overview

Acipimox is a niacin derivative used as a hypolipidemic agent that inhibits lipolysis, reducing plasma free fatty acid (FFA) concentrations. When combined with insulin, this combination has been studied for its effects on insulin sensitivity, glucose metabolism, and β-cell function. Acipimox significantly lowers serum triglyceride levels and, when used with insulin, can improve insulin-stimulated glucose uptake, predominantly affecting glycogen formation. Short-term acipimox treatment appears to improve insulin sensitivity, while long-term treatment may induce insulin resistance.

Targets

HCAR2 (Hydroxycarboxylic acid receptor 2)HCAR3 (Hydroxycarboxylic acid receptor 3)INSR (Insulin receptor)

Beyond the preview

Go deeper on acipimox + insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acipimox + insulin.

Explore the full profile